Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-center, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of KN046 in Subjects With Advanced Solid Tumors

Trial Profile

An Open-Label, Multi-center, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of KN046 in Subjects With Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erfonrilimab (Primary)
  • Indications Malignant thymoma; Mesothelioma; Multiple myeloma; Nasopharyngeal cancer; Non-small cell lung cancer; Renal cancer; Small cell lung cancer; Solid tumours; Thoracic neoplasms; Thymic epithelial tumour; Thymoma; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors Jiangsu Alphamab Biopharmaceuticals

Most Recent Events

  • 31 Jan 2021 Results (As of Jan 20, 2020; n=5) for safety,efficacy of KN046 in thoracic tumors, presented at the 2020 World Conference on Lung Cancer
  • 31 May 2020 Results (n=29) of analysis assessing preliminary efficacy and safety data of KN046 in patients failed on prior immune checkpoint inhibitors presented at the 56th Annual Meeting of the American Society of Clinical Oncology
  • 21 Oct 2019 Planned End Date has been changed to 1 Apr 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top